Cover Image
市場調查報告書

Oncodesign SA - 產品平台分析

Oncodesign SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293910
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Oncodesign SA - 產品平台分析 Oncodesign SA - Product Pipeline Review - 2015
出版日期: 2015年02月24日 內容資訊: 英文 24 Pages
簡介

Oncodesign是以法國為據點的生物製藥公司,提供治療癌症領域的遞藥發明及藥理學評估服務,尤其是抗癌治療的前臨床性評估。

本報告提供Oncodesign SA的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Oncodesign SA的基本資料

Oncodesign SA概要

  • 主要資訊
  • 企業資料

Oncodesign SA:R&D概要

  • 主要的治療範圍

Oncodesign SA:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Oncodesign SA:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Oncodesign SA:藥物簡介

  • Small Molecules to Inhibit LRRK-2 for Parkinson's Disease
  • Small Molecules to Inhibit Salt-Inducible Kinase 2 for Ovarian Cancer
  • Small Molecules to Inhibit Transforming Growth Factor Beta Receptor II for Cancer
  • Small Molecules to Inhibit Kinase for Neurodegenerative Diseases
  • Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis

Oncodesign SA:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Oncodesign SA:暫停中的計劃

Oncodesign SA:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06799CDB

Summary

Global Markets Direct's, 'Oncodesign SA - Product Pipeline Review - 2015', provides an overview of the Oncodesign SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Oncodesign SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Oncodesign SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Oncodesign SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Oncodesign SA's pipeline products

Reasons to buy

  • Evaluate Oncodesign SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Oncodesign SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Oncodesign SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Oncodesign SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oncodesign SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Oncodesign SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Oncodesign SA Snapshot
    • Oncodesign SA Overview
    • Key Information
    • Key Facts
  • Oncodesign SA - Research and Development Overview
    • Key Therapeutic Areas
    • Oncodesign SA - Pipeline Review
  • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Oncodesign SA - Pipeline Products Glance
    • Oncodesign SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Oncodesign SA - Drug Profiles
    • Small Molecules to Inhibit LRRK-2 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Salt-Inducible Kinase 2 for Ovarian Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Transforming Growth Factor Beta Receptor II for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kinase for Neurodegenerative Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Oncodesign SA - Pipeline Analysis
    • Oncodesign SA - Pipeline Products by Target
    • Oncodesign SA - Pipeline Products by Molecule Type
    • Oncodesign SA - Pipeline Products by Mechanism of Action
  • Oncodesign SA - Dormant Projects
  • Oncodesign SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Oncodesign SA, Key Information
  • Oncodesign SA, Key Facts
  • Oncodesign SA - Pipeline by Indication, 2015
  • Oncodesign SA - Pipeline by Stage of Development, 2015
  • Oncodesign SA - Monotherapy Products in Pipeline, 2015
  • Oncodesign SA - Partnered Products in Pipeline, 2015
  • Oncodesign SA - Partnered Products/ Combination Treatment Modalities, 2015
  • Oncodesign SA - Preclinical, 2015
  • Oncodesign SA - Discovery, 2015
  • Oncodesign SA - Pipeline by Target, 2015
  • Oncodesign SA - Pipeline by Molecule Type, 2015
  • Oncodesign SA - Pipeline Products by Mechanism of Action, 2015
  • Oncodesign SA - Dormant Developmental Projects,2015

List of Figures

  • Oncodesign SA - Pipeline by Top 10 Indication, 2015
  • Oncodesign SA - Pipeline by Stage of Development, 2015
  • Oncodesign SA - Monotherapy Products in Pipeline, 2015
  • Oncodesign SA - Partnered Products in Pipeline, 2015
  • Oncodesign SA - Pipeline by Top 10 Target, 2015
  • Oncodesign SA - Pipeline by Top 10 Molecule Type, 2015
  • Oncodesign SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top